Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses - MAD
Study identifier:D2060C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A randomised, single-blind, placebo-controlled, single centre, Phase I study in healthy volunteers to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4017 after repeated ascending oral doses
Medical condition
Diabetes mellitus type 2
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD4017, Placebo
Sex
Male
Actual Enrollment
107
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Feb 2009
Primary Completion Date: -
Study Completion Date: 01 May 2009
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Other
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
NA
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 AZD4017 in ascending doses (start dose 75mg od) | Drug: AZD4017 ascending multiple doses(start dose 75mg od), oral suspension |
| Placebo Comparator: 2 Placebo | - |
Contacts
Investigators
Principal Investigator
Marianne Hartford
AstraZeneca Clinical Pharmacolgy Unit Sahlgrenska University Hospital SE-413 45 Göteborg Sweden
